-
| Exchange | NASDAQ |
|---|---|
| CurrencyCode | USD |
| ISIN | US45254E1073 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | 51M |
|---|---|
| PE Ratio | None |
| Target Price | 11.7 |
| Beta | -0.26 |
| Dividend Yield | None |
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 that is in Phase 1/2a clinical trial for the treatment of patients with solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for IMRX using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025